MarketPeel
Pricing
…
NS

Nancy Lynn Md Snyderman

LYRA
DIRECTOR · LYRA THERAPEUTICS, INC. · CIK 0001675198
FILING MIX · LIFETIME74%/26%
BUYS
43
SELLS
15
TOTAL VALUE
$4.68M
COMPANIES
2
ACTIVE SINCE
May 2020
HOLDINGS NOW
32,000
AVG SELL PX
$46.75
TRADE KIND
SHOWING 58 / 58
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Nancy Lynn Md Snyderman, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+100.00%+11.32%-1.54%+12.86%+12.86%—
14d2+100.00%+13.80%+2.05%+11.75%+11.75%—
30d2+100.00%+17.85%+3.98%+13.88%+13.88%—
60d2+100.00%+33.34%+1.58%+31.76%+31.76%—
90d2+100.00%+35.93%+2.15%+33.78%+33.78%—
180d2+50.00%-1.55%+3.93%-5.48%-5.48%—
1y2+50.00%-18.90%+11.42%-30.32%-30.32%—
2y2+50.00%-22.95%+14.69%-37.64%-37.64%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
LYRA · 32,000 shares · as of May 14, 2025
08,00016,00024,00032,00020212022202320242025SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 43 buys / 15 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ALKS
ALKERMES PLC.
PURCHASE
16,524$46.72$772.0K59,867Aug 3, 2026Aug 3, 2026 ↗View →
ALKS
ALKERMES PLC.
SALE
16,524——0Aug 3, 2026Aug 3, 2026 ↗View →
ALKS
ALKERMES PLC.
SALE
44,472$50.35$2.24M15,395Aug 3, 2026Aug 3, 2026 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
27,948$46.72$1.31M43,343Aug 3, 2026Aug 3, 2026 ↗View →
ALKS
ALKERMES PLC.
SALE
27,948——0Aug 3, 2026Aug 3, 2026 ↗View →
ALKS
ALKERMES PLC.
SALE
1,475$36.95$54.5K15,395May 21, 2026May 22, 2026 ↗View →
ALKS
ALKERMES PLC.
SALE
6,142——0May 21, 2026May 22, 2026 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
6,142——16,870May 21, 2026May 22, 2026 ↗View →
ALKS
ALKERMES PLC.
PURCHASEGRANT
Stock grant
5,409——5,409May 20, 2026May 22, 2026 ↗View →
ALKS
ALKERMES PLC.
PURCHASEGRANT
Stock grant
11,538——11,538May 20, 2026May 22, 2026 ↗View →
ALKS
ALKERMES PLC.
SALE
8,013——0May 31, 2025Jun 2, 2025 ↗View →
ALKS
ALKERMES PLC.
SALE
1,924$30.61$58.9K10,728May 31, 2025Jun 2, 2025 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
8,013——12,652May 31, 2025Jun 2, 2025 ↗View →
ALKS
ALKERMES PLC.
PURCHASEGRANT
Stock grant
6,142——6,142May 21, 2025May 23, 2025 ↗View →
ALKS
ALKERMES PLC.
PURCHASEGRANT
Stock grant
13,474——13,474May 21, 2025May 23, 2025 ↗View →
LYRA
LYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
32,000——32,000May 14, 2025May 16, 2025 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
6,104——6,104Jun 29, 2024Jul 1, 2024 ↗View →
ALKS
ALKERMES PLC.
SALE
6,104——0Jun 29, 2024Jul 1, 2024 ↗View →
ALKS
ALKERMES PLC.
SALE
1,465$24.10$35.3K4,639Jun 29, 2024Jul 1, 2024 ↗View →
LYRA
LYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
30,000——30,000Jun 13, 2024Jun 14, 2024 ↗View →
ALKS
ALKERMES PLC.
PURCHASEGRANT
Stock grant
8,013——8,013May 31, 2024Jun 4, 2024 ↗View →
ALKS
ALKERMES PLC.
PURCHASEGRANT
Stock grant
17,492——17,492May 31, 2024Jun 4, 2024 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
313$24.24$7.6K15,990Nov 17, 2023Jun 4, 2024 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
350$44.75$15.7K17,850Nov 17, 2023Jun 4, 2024 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
254$30.72$7.8K12,986Nov 17, 2023Jun 4, 2024 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
256$16.52$4.2K13,079Nov 17, 2023Jun 4, 2024 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
448$24.55$11.0K22,848Nov 17, 2023Jun 4, 2024 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
119——6,104Nov 17, 2023Jun 4, 2024 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
231$30.86$7.1K11,785Nov 17, 2023Jun 4, 2024 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
230$18.45$4.2K11,739Nov 17, 2023Jun 4, 2024 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
324$46.72$15.1K16,524Nov 17, 2023Jun 4, 2024 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
284$57.11$16.2K14,484Nov 17, 2023Jun 4, 2024 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
548$46.72$25.6K27,948Nov 17, 2023Jun 4, 2024 ↗View →
LYRA
LYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,000——20,000Jun 30, 2023Jul 5, 2023 ↗View →
ALKS
ALKERMES PLC.
PURCHASEGRANT
Stock grant
5,985——5,985Jun 29, 2023Jun 30, 2023 ↗View →
ALKS
ALKERMES PLC.
PURCHASEGRANT
Stock grant
12,732——12,732Jun 29, 2023Jun 30, 2023 ↗View →
ALKS
ALKERMES PLC.
PURCHASEGRANT
Stock grant
5,957——5,957Jul 7, 2022Jul 8, 2022 ↗View →
ALKS
ALKERMES PLC.
PURCHASEGRANT
Stock grant
11,554——11,554Jul 7, 2022Jul 8, 2022 ↗View →
LYRA
LYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
7,250——7,250Jun 16, 2022Jun 21, 2022 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
7,585——16,951Jun 14, 2022Jun 16, 2022 ↗View →
ALKS
ALKERMES PLC.
SALE
7,585——0Jun 14, 2022Jun 16, 2022 ↗View →
ALKS
ALKERMES PLC.
SALE
695$27.19$18.9K16,256Jun 14, 2022Jun 16, 2022 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
427$23.43$10.0K9,366Mar 4, 2022Mar 8, 2022 ↗View →
ALKS
ALKERMES PLC.
SALE
1,339$22.11$29.6K8,939Dec 2, 2021Dec 3, 2021 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
5,578——10,278Dec 2, 2021Dec 3, 2021 ↗View →
ALKS
ALKERMES PLC.
SALE
5,578——0Dec 2, 2021Dec 3, 2021 ↗View →
ALKS
ALKERMES PLC.
PURCHASEGRANT
Stock grant
15,677——15,677Jun 14, 2021Jun 16, 2021 ↗View →
ALKS
ALKERMES PLC.
PURCHASEGRANT
Stock grant
7,585——7,585Jun 14, 2021Jun 16, 2021 ↗View →
LYRA
LYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
7,250——7,250May 26, 2021May 28, 2021 ↗View →
ALKS
ALKERMES PLC.
SALE
6,104——0May 20, 2021May 21, 2021 ↗View →
ALKS
ALKERMES PLC.
PURCHASE
6,104——6,104May 20, 2021May 21, 2021 ↗View →
ALKS
ALKERMES PLC.
SALE
1,404$21.92$30.8K4,700May 20, 2021May 21, 2021 ↗View →
LYRA
LYRA THERAPEUTICS, INC.
PURCHASE
1,025$9.72$10.0K1,025Dec 16, 2020Dec 17, 2020 ↗View →
ALKS
ALKERMES PLC.
PURCHASEGRANT
Stock grant
11,509——11,509Dec 2, 2020Dec 4, 2020 ↗View →
ALKS
ALKERMES PLC.
PURCHASEGRANT
Stock grant
5,578——5,578Dec 2, 2020Dec 4, 2020 ↗View →
LYRA
LYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
14,500——14,500Oct 27, 2020Oct 29, 2020 ↗View →
ALKS
ALKERMES PLC.
PURCHASEGRANT
Stock grant
6,104——6,104May 20, 2020May 22, 2020 ↗View →
ALKS
ALKERMES PLC.
PURCHASEGRANT
Stock grant
12,823——12,823May 20, 2020May 22, 2020 ↗View →
Other insiders · LYRA
Loading peer insiders…
About this filer
CIK 0001675198
ROLE
Director
PRIMARY
LYRA
COMPANIES
2
ACTIVE SINCE
May 2020
MARKETPEEL · /INSIDER/0001675198DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback